Pfizer strikes Innovent deal worth up to $10.5B for a dozen cancer programs
On the eve of this year’s ASCO annual meeting, Pfizer said it is teaming up with China’s Innovent Biologics to advance a portfolio of 12 early-stage antibody-dr...
On the eve of this year’s ASCO annual meeting, Pfizer said it is teaming up with China’s Innovent Biologics to advance a portfolio of 12 early-stage antibody-drug conjugates and multi-specific antibodies in a deal that ...